1443. Deputy Matt Carthy asked the Minister for Health if her Department or the HSE has engaged with a company (details supplied) and the relevant neurology and ataxia services regarding the roll-out of skyclarys (omaveloxolone) following its approval for reimbursement; if a national implementation or treatment pathway has been agreed; the arrangements being made to ensure eligible patients can be assessed and prescribed the treatment without unnecessary delay; and if she will make a statement on the matter. [65855/26]

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.